285 reports of this reaction
1.5% of all AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE reports
#17 most reported adverse reaction
CHEST PAIN is the #17 most commonly reported adverse reaction for AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, manufactured by Novartis Pharmaceuticals Corporation. There are 285 FDA adverse event reports linking AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE to CHEST PAIN. This represents approximately 1.5% of all 18,930 adverse event reports for this drug.
Patients taking AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE who experience chest pain should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CHEST PAIN is a less commonly reported adverse event for AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to chest pain, the following adverse reactions have been reported for AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE:
The following drugs have also been linked to chest pain in FDA adverse event reports:
CHEST PAIN has been reported as an adverse event in 285 FDA reports for AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
CHEST PAIN accounts for approximately 1.5% of all adverse event reports for AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, making it a notable side effect.
If you experience chest pain while taking AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.